Emerging drugs for pneumococcal pneumonia

Expert Opinion on Emerging Drugs

Volumn 16, Issue 3, 2011, Pages 459-477

  Falcó, Vicenç ^a   Sánchez, Ana ^a   Pahissa, Albert ^a   Rello, Jordi ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

cephalosporins; fluorquinolones; penicillin; pneumococcal pneumonia

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; BC 3781; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CEFUROXIME; CETHROMYCIN; CLARITHROMYCIN; DELAFLOXACIN; DELAMANID; DOXYCYCLINE; ERYTHROMYCIN; FLOPRISTIN; GATIFLOXACIN; GEMIFLOXACIN; ICLAPRIM; JNJ 32729463; KETOLIDE; LEVOFLOXACIN; LINOPRISTIN; MACROLIDE; MODITHROMYCIN; MOXIFLOXACIN; NEMONOXACIN; OMADACYCLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RADEZOLID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; ZABOFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; DRUG RESEARCH; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STREPTOCOCCUS PNEUMONIA;

ANTI-INFECTIVE AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; CLINICAL TRIALS, PHASE IV AS TOPIC; DRUG RESISTANCE, MICROBIAL; HUMANS; PNEUMONIA, PNEUMOCOCCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80051994902     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2011.576669     Document Type: Review

References (151)

1. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. In: Atkinson W, Wolfe S, Hamborsky J, McIntyre L. editors, 11th edition. Public Health Foundation, Washington DC; 2009. Available from: Http://www.cdc. gov/vaccines/pubs/pinkbook/downloads/ pneumo.pdf
2. Ardanuy C, Tubau F, Pallares R, et al. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin Infect Dis 2009;48:57-64
3. Kellner JD, Vanderkooi OG, MacDonald J, et al. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: Update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009;49:205-12
4. Rodenburg GD, de Greeff SC, Jansen AG, et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 2010;16:816-23
5. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201:32-41
6. Williams SR, Mernagh PJ, Lee MH, Tan JT. Changing epidemiology of invasive pneumococcal disease in Australian children after introduction of a 7-valent pneumococcal conjugate vaccine. Med J Aust 2011;194:116-20
7. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005;294:2043-51 This is one of the most important articles that reflects the epidemiological changes in pneumococcal invasive disease after the introduction of the 7-valent pneumococcal conjugated vaccine in children.
8. O'Brien KL, Millar EV, Zell ER, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and un-immunized children in a community-randomized trial. J Infect Dis 2007;196:1211-20
9. Millar EV, Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis 2008;47:989-96
10. Singleton R, Hennessy T, Bulkow L, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children high levels of 7-Valent pneumococcal conjugate vaccine coverage. JAMA 2007;297:1784-92
11. Jacobs MR, Good CE, Bajaksouzian S, Windau AR. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin Infect Dis 2008;47:1388-95
12. Byington CL, Samore MH, Stoddard GJ, et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: Emergence of nonvaccine serogroups. Clin Infect Dis 2005;41:21-9
13. Munoz-Almagro C, Jordan I, Gene A, et al. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008;46:174-82
14. Kyaw MH, Rose CE Jr, Fry AM, et al. Active bacterial core surveillance program of the emerging infections program network. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 2005;192:377-86
15. Ardanuy C, Rolo D, Fenoll A, et al. Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. J Antimicrob Chemother 2009;64:507-10
16. Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 2007;298:1772-8
17. Gertz RE Jr, Li Z, Pimenta FC, et al.; Active Bacterial Core Surveillance Team. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J Infect Dis 2010;201:770-5
18. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: Correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003;37:230-7
19. Jedrzejas MJ. Pneumococcal virulence factors: Structure and function. Microbiol Mol Biol Rev 2001;65:187-207
20. Jedrzejas MJ. Extracellular virulence factors of Streptococcus pneumoniae. Front Biosci 2004;9:891-914
21. Calbo E, Garau J. Of mice and men: Innate immunity in pneumococcal pneumonia. Int J Antimicrob Agents 2010;35:107-13
22. Calbo E, Alsina M, Rodriguez-Carballeira M, et al. The impact of time on the systemic inflammatory response in pneumococcal pneumonia. Eur Respir J 2010;35:614-18
23. Austrian R, Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964;60:759-76 The importance of this paper is its historical value in the field of pneumococcal disease.
24. Deghmane AE, Alonso JM, Taha MK. Emerging drugs for acute bacterial meningitis. Expert Opin Emerg Drugs 2009;14:381-93
25. Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: Have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005;41:139-48
26. Low DE. Changing trends in antimicrobial-resistant pneumococci: It's not all bad news. Clin Infect Dis 2005;41(Suppl 4):S228-33
27. Talbot TR, Poehling KA, Hartert TV, et al. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2004;39:641-8
28. Kyaw MH, Lynfield R, Schaffner W. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006;354:1455-63
29. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-46
30. Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004;113:443-9
31. Black S, Shinefield H, Baxter R, et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 2004;23:485-9
32. Stephens DS, Zughaier SM, Whitney CG, et al.; Georgia Emerging Infections Program. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: Population-based assessment. Lancet 2005;365:855-63
33. Byington CL, Samore MH, Stoddard GJ, et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: Emergence of nonvaccine serogroups. Clin Infect Dis 2005;41:21-9
34. Waterer GW, Buckingham SC, Kessler LA, et al. Decreasing beta-lactam resistance in Pneumococci from the Memphis region: Analysis of 2,152 isolates From 1996 to 2001. Chest 2003;124:519-25
35. Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009;360:244-56
36. Vanderkooi OG, Low DE, Green K, et al.; Toronto Invasive Bacterial Disease Network. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005;40:1288-97
37. Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, et al. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: A multicenter study. Clin Infect Dis 1997;24:1052-9
38. Klugman KP, McGee L. Resurgence of the multiresistant pneumococcus in the United States: A commentary. Pediatr Infect Dis J 2007;26:473-4
39. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 2007;26:123-8
40. Porat N, Amit U, Givon-Lavi N, et al. Increasing importance of multidrug-resistant serotype 6A Streptococcus pneumoniae clones in acute otitis media in southern Israel. Pediatr Infect Dis J. 2010;29:126-30
41. Dagan R, Givon-Lavi N, Leibovitz E, et al. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 2009;199:776-85
42. Falco V, Almirante B, Jordano Q, et al. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: Is penicillin useful against intermediately resistant strains? J Antimicrob Chemother 2004;54:481-8
43. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995;333:474-80
44. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000;90:223-9
45. Aspa J, Rajas O, Rodriguez de Castro F, et al. Drug-resistant pneumococcal pneumonia: Clinical relevance and related factors. Clin Infect Dis 2004;38:787-98
46. Metlay JP, Hofmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000;30:520-8
47. Peterson LR. Penicillins for treatment of pneumococcal pneumonia: Does in vitro resistance really matter? Clin Infect Dis 2006;42:224-33 This paper provides an extensive review of the utility of penicillin in the treatment of pneumococcal pneumonia.
48. Mufson MA, Chan G, Stanek RJ. Penicillin resistance not a factor in outcome from invasive Streptococcus pneumoniae community-acquired pneumonia in adults when appropriate empiric therapy is started. Am J Med Sci 2007;333:161-7
49. Tleyjeh IM, Tlaygeh HM, Hejal R, et al. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: A systematic review and meta-analysis. Clin Infect Dis 2006;42:788-97
50. File TM Jr, Tan JS, Boex JR. The clinical relevance of penicillin-resistant Streptococcus pneumoniae: A new perspective. Clin Infect Dis 2006 42:798-800
51. Bishai W. The in vivo-in vitro paradox in pneumococcal respiratoy tract infections. J Antimicrob Chemoher 2002;49:433-6
52. Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: Coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis 2009;48:1596-600 This paper focus on the reasons why penicillin susceptibility breakpoints for pneumococcus causing pneumonia have been changed.
53. Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: Results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis 2002;34(Suppl 1):S4-16
54. Farrell DJ, Jenkins SG, Brown SD, et al. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg Infect Dis 2005;11:851-8
55. Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001;286:1857-62
56. Klugman KP, Lonks JR. Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis 2005;11:802-7
57. Perez-Trallero E, Fernandez-Mazarrasa C, Garcia-Rey C, et al. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: Results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001;45:3334-40
58. Song JH, Jung SI, Ko KS, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004;48:2101-7
59. Stephens DS, Zughaier SM, Whitney CG, et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: Population-based assessment. Lancet 2005;365:855-63
60. Dagan R, Leibovitz E, Leiberman A, Yagupsky P. Clinical significance of antibiotic resistance in acute otitis media and implication of antibiotic treatment on carriage and spread of resistant organisms. Pediatr Infect Dis J 2000;19(5 Suppl):S57-65
61. Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis 2000;31:613-15
62. Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000;31:1008-11
63. Waterer GW, Wunderink RG, Jones CB. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 2000;118:1839-40
64. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;35:556-64
65. Van Kerkhoven D, Peetermans WE, Verbist L, Verhaeg en J. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother 2003;51:691-6
66. Kays MB, Wack MF, Smith DW, Denys GA. Azithromycin treatment failure in community-acquired pneumonia caused by Streptococcus pneumoniae resistant to macrolides by a 23S rRNA mutation. Diagn Microbiol Infect Dis 2002;43:163-5
67. Daneman N, McGeer A, Green K, Low DE. Macrolide resistance in bacteremic pneumococcal disease: Implications for patient management. Clin Infect Dis 2006;43:432-8
68. Butler JC, Lennox JL, McDougal LK, et al. Macrolide-resistant pneumococcal endocarditis and epidural abscess that develop during erythromycin therapy. Clin Infect Dis 2003;36:e19-25
69. Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002;346:630-1
70. Daneman N, Low DE, McGeer A, et al. At the threshold: Defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia. Clin Infect Dis 2008;46:1131-8
71. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality in severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004;170:440-4 This is a prospective observational study that addresses the issue of combination therapy with b-lactams and macrolides for bacteremic pneumococcal pneumonia.
72. Rodriguez A, Mendia A, Sirvent JM, et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007;35:1493-8
73. Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010;36:610-20
74. Brueggemann AB, Coffman SL, Rhomberg P, et al. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother 2002;46:680-8
75. Pletz MW, Shergill AP, McGee L, et al.; Active Bacterial Core Surveillance Team. Prevalence of first-step mutants among levofloxacin- susceptible invasive isolates of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2006;50:1561-3
76. Pletz MW, McGee L, Jorgensen J, et al. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: Evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother 2004;48:3491-7
77. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated to fluorquinolone resistance. Clin Infect Dis 2005;41:118-21
78. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747
79. Kays MB, Smith DW, Wack ME, Denys GA. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 2002;22:395-9
80. Anderson KB, Tan JS, File TM Jr, et al. Emergence of levofloxacin- resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003;37:376-81
81. Scheld WM. Maintaining fluoroquinolone class efficacy: Review of influencing factors. Emerg Infect Dis 2003;9:1-9
82. Ho PL, Tse WS, Tsang KW, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: A case-control study. Clin Infect Dis 2001;32:701-7
83. Chiou CC. Does penicillin remain the drug of choice for pneumococcal pneumonia in view of emerging in vitro resistance? Clin Infect Dis 2006;42:234-7
84. Van Bambeke F, Reinert RR, Appelbaum PC, et al. Multidrug-resistant Streptococcus pneumoniae infections. Current and future therapeutic options. Drugs 2007;67:2355-882
85. Garau J. Treatment of drug resistant pneumococcal pneumonia. Lancet Infect Dis 2002;2:404-15 This paper presents a comprehensive review of the antibiotic treatment of pneumococcal pneumonia.
86. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-72
87. Jones RN, Andes DR, Mandell LA, et al. Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2002;44:93-100
88. Lode H, File TM Jr, Mandell L, et al. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: A randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther 2002;24:1915-36
89. Norrby SR, Petermann W, Willcox PA, et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998;30:397-404
90. Fogarty C, Siami G, Kohler R, et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis 2004;38(Suppl 1):S16-23
91. Leroy O, Saux P, Bedos JP, Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005;128:172-83
92. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002;46:1746-54
93. Torres A, Garau J, Arvis P, et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: The MOTIV study-a randomized clinical trial. Clin Infect Dis 2008;46:1499-509
94. Anzueto A, Niederman MS, Pearle J, et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): Efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006;42:73-81
95. Shams WE, Evans ME. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections. Drugs 2005;65:949-91
96. Kahn JB, Bahal N, Wiesinger BA, Xiang J. Cumulative clinical trial experience with levofloxacin for patients with community-acquired pneumonia-associated pneumococcal bacteremia. Clin Infect Dis 2004;38(Suppl 1):S34-42
97. Vardakas KZ, Siempos II, Grammatikos A, et al. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: A meta-analysis of randomized controlled trials. CMAJ 2008;179:1269-77
98. File TM Jr. Appropriate use of antimicrobials for drug-resistant pneumonia: Focus on the significance of beta-lactam-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;34 (Suppl 1):S17-26
99. Contopoulos-Ioannidis DG, Ioannidis JP, Chew P, Lau J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother 2001;48:691-703
100. Rahav G, Fidel J, Gibor Y, Shapiro M. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia. Int J Antimicrob Agents 2004;24:181-4
101. Plouffe J, Schwartz DB, Kolokathis A, et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group. Antimicrob Agents Chemother 2000;44:1796-802
102. Drehobl MA, De Salvo MC, Lewis DE, Breen JD. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 2005;128:2230-7
103. D'Ignazio J, Camere MA, Lewis DE, et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. Antimicrob Agents Chemother 2005;49:4035-41
104. Hagberg L, Torres A, van Rensburg D, et al. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection 2002;30:378-86
105. Pullman J, Champlin J, Vrooman PS Jr. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int J Clin Pract 2003;57:377-84
106. Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004;54:515-23
107. Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003;47:1867-74
108. Doern GV, Heilmann KP, Huynh HK, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001;45:1721-9
109. Ailani RK, Agastya G, Ailani RK, et al. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Arch Intern Med 1999;159:266-70
110. Pharmaprojects. Informa-Pipeline (http://informa-pipeline.citeline.com) and Citeline (http://informa.citeline.com)
111. San Pedro GS, Cammarata SK, Oliphant TH, et al.; Linezolid Community-Acquired Pneumonia Study Group. Linezolid versus ceftriaxone/ cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis 2002;34:720-8
112. Hoban DJ, Bouchillon SK, Johnson BM, et al. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial. Diagn Microbiol Infect Dis 2005;52:215-27
113. McKeage K, Keating GM. Tigecycline: In community-acquired pneumonia. Drugs 2008;68:2633-44
114. Tanaseanu C, Bergallo C, Teglia O, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008;61:329-38
115. Dartois N, Castaing N, Gandjini H, et al.; Tigecycline 313 Study Group. Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience. J Chemother 2008;20(Suppl 1):28-35
116. Tanaseanu C, Milutinovic S, Calistru PI, et al. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med 2009;9:44
117. Bergallo C, Jasovich A, Teglia O, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: Results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009;63:52-61
118. Falagas ME, Metaxas EI. Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization. Expert Rev Anti Infect Ther 2009;7:913-23
119. Patel SN, Pillai DR, Pong-Porter S, et al. In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008. J Antimicrob Chemother 2009;64:659-60
120. Kosowska K, Hoellman DB, Lin G, et al. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005;49:1932-42
121. McGee L, Biek D, Ge Y, et al. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2009;53:552-6
122. Jacobs MR, Good CE, Windau AR, et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2010;54:2716-19
123. Rafie S, MacDougall C, James CL. Cethromycin: A promising new ketolide antibiotic for respiratory infections. Pharmacotherapy 2010;30:290-303
124. Hammerschlag MR, Sharma R. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections. Expert Opin Investig Drugs 2008;17:387-400
125. Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008;46:1142-51
126. Baughman R. and the US Synercid CAP Study Group. Randomized, double-blind, comparative, multicenter study of quinupristin-dalfopristin (Q/D, RPR59500, Synercid) versus combination of ceftriaxone and erythromycin in the treatment of acute community-acquired bacterial pneumonia (CAP) [abstract 2321]. In Programs and abstracts of the 20th International Congress of Chemotherapy; Sydney, Australia; 1997
127. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: A 20- year longitudinal study, 1978-1997. Am J Med 1999;107:34S-43S
128. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001;161:1837-42
129. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003;36:389-95
130. Weiss K, Low DE, Cortes L, et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004;11:589-93
131. Mufson MA, Stanek RJ. Revisiting combination antibiotic therapy for community-acquired invasive Streptococcus pneumoniae pneumonia. Clin Infect Dis 2006;42:304-6
132. Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. Chest 2007;131:466-73
133. Dwyer R, Ortqvist A, Aufwerber E, et al. Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2006;25:518-21
134. Chokshi R, Restrepo MI, Weeratunge N, et al. Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2007;26:447-51
135. Aspa J, Rajas O, Rodriguez de Castro F, et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 2006;27:1010-19
136. Periti P, Mazzei T. Antibiotic-induced release of bacterial cell wall components in the pathogenesis of sepsis and septic shock: A review. J Chemother 1998;10:427-48
137. Ianoro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000;292:156-63
138. Anderson R, Steel HC, Cockeran R, et al. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro. J Antimicrob Chemother 2007;60:1155-8
139. Anderson R, Steel HC, Cockeran R, et al. Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumoniae. J Antimicrob Chemother 2007;59:224-9
140. Gleason PP, Meehan TP, Fine JM, et al. Association between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999;159:2562-72
141. Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: A one year prospective study of 346 consecutive patients. Thorax 1996;51:179-84
142. Ragnar Norrby S, for the Nordic Atypical Pneumonia Study Group. Atypical pneumonia in the Nordic countries: Aetiology and clinical results of a trial comparing fleroxacin and doxycycline. J Antimicrob Chemother 1997;39:499-508
143. Calbo E, Alsina M, Rodriguez-Carballeira M, et al. Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: Effects of treatment with a beta-lactam versus a fluoroquinolone. Antimicrob Agents Chemother 2008;52:2395-402
144. Waterer GW. Monotherapy versus combination antimicrobial therapy for pneumococcal pneumonia. Curr Opin Infect Dis 2005;18:157-63
145. Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008;121:1002-7
146. Mortensen EM, Pugh MJ, Copeland LA, et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 2008;31:611-17
147. Garcia-Vidal C, Calbo E, Pascual V, et al. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 2007;30:951-6
148. Snijders D, Daniels JM, de Graaff CS, et al. Efficacy of corticosteroids in community-acquired pneumonia: A randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010;181:975-82 A randomized trial that demonstrates the lack of efficacy of corticosteroids for community-acquired pneumonia.
149. Meduri GU, Bell WA, Confalonieri M. Glucocorticoid treatment in community-acquired pneumonia without severe sepsis: No evidence of efficacy. Am J Respir Crit Care Med 2010;181:880-2
150. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
151. Laterre PF, Garber G, Levy H, et al. Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study. Crit Care Med 2005;33:952-61